SG11202007226UA - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
SG11202007226UA
SG11202007226UA SG11202007226UA SG11202007226UA SG11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
sleep apnea
treating sleep
treating
Prior art date
Application number
SG11202007226UA
Other languages
English (en)
Inventor
Lawrence G Miller
Barry Wohl
Walter J Lunsmann
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of SG11202007226UA publication Critical patent/SG11202007226UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007226UA 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea SG11202007226UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
SG11202007226UA true SG11202007226UA (en) 2020-08-28

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007226UA SG11202007226UA (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Country Status (14)

Country Link
US (3) US11911351B2 (es)
EP (1) EP3746126B1 (es)
JP (2) JP7422666B2 (es)
KR (1) KR20200115598A (es)
CN (2) CN111670050A (es)
AU (1) AU2019214891B2 (es)
BR (1) BR112020015316A2 (es)
CA (1) CA3089712A1 (es)
EA (1) EA202091597A1 (es)
IL (1) IL276247A (es)
MA (1) MA52861A (es)
MX (2) MX2020008086A (es)
SG (1) SG11202007226UA (es)
WO (1) WO2019152475A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012729A (es) * 2017-04-28 2019-12-19 Brigham & Womens Hospital Inc Metodos y composiciones para el tratamiento de apnea del sue?o.
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
CA3210092A1 (en) * 2021-03-04 2022-09-09 Lawrence G. Miller Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
EP4313153A1 (en) * 2021-03-24 2024-02-07 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
WO2022235726A1 (en) 2021-05-04 2022-11-10 Apnimed, Inc. (Delaware) Solid forms of (r)-oxybutynin d-malate
JP2024523876A (ja) * 2021-06-17 2024-07-02 アプニメッド,インコーポレイテッド(デラウェア) 睡眠時無呼吸を治療するためのノルエピネフリン再取り込み阻害剤
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α2-腎上腺素受體亞型C(α-2C)拮抗劑與蕈毒鹼受體拮抗劑之組合
KR20240124995A (ko) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (es) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DK0866711T3 (da) 1995-10-24 2006-11-27 Gruenenthal Gmbh Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
CN1396829A (zh) 2000-02-24 2003-02-12 法玛西雅厄普约翰美国公司 新的药物联合形式
WO2002089843A1 (en) 2001-03-13 2002-11-14 Millenium Pharmaceuticals, Inc. Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2523567A1 (en) 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060039867A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
WO2006055854A2 (en) 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
AU2005319367B2 (en) 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006102029A2 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1868602A1 (en) 2005-04-15 2007-12-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20070021927A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
WO2008066750A1 (en) 2006-11-22 2008-06-05 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008124128A2 (en) 2007-04-09 2008-10-16 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009023820A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
WO2009086046A1 (en) 2007-12-21 2009-07-09 Eurand, Inc. Orally disintegrating tablet compositions of temazepam
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
CN102939008A (zh) 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
EP2672972B1 (en) 2011-01-28 2020-11-04 Pfantastic Medical Research Institute, LLC Methods for treating obstructive sleep apnea
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc (r)−オキシブチニンおよび(r)−デスエチルオキシブチニンによる平滑筋機能亢進の処置
DK2964185T3 (da) 2013-03-05 2022-02-14 Requis Pharmaceuticals Inc Præparater til behandlingen af søvnrelaterede luftvejslidelser
WO2016062277A1 (zh) 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 驱虫药用于制备抗癌医药组合物中的应用
HUE047169T2 (hu) 2015-04-27 2020-04-28 Arena Pharm Inc 5-HT2C receptor agonisták és készítmények és felhasználási eljárások
EP3324975B1 (en) 2015-07-22 2022-05-18 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
WO2017031319A1 (en) 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
MX2019012729A (es) * 2017-04-28 2019-12-19 Brigham & Womens Hospital Inc Metodos y composiciones para el tratamiento de apnea del sue?o.
CN111818946A (zh) 2018-01-31 2020-10-23 国家儿童医院研究所 2c型肢带型肌营养不良的基因疗法
US20220096401A1 (en) 2019-02-08 2022-03-31 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea

Also Published As

Publication number Publication date
JP7422666B2 (ja) 2024-01-26
US20210038541A1 (en) 2021-02-11
EP3746126B1 (en) 2024-07-31
US20220378724A1 (en) 2022-12-01
AU2019214891A1 (en) 2020-08-20
CN118384147A (zh) 2024-07-26
MA52861A (fr) 2021-05-05
CN111670050A (zh) 2020-09-15
EA202091597A1 (ru) 2020-10-22
BR112020015316A2 (pt) 2020-12-08
WO2019152475A1 (en) 2019-08-08
IL276247A (en) 2020-09-30
MX2020008086A (es) 2021-02-15
CA3089712A1 (en) 2019-08-08
JP2021516218A (ja) 2021-07-01
JP2023181322A (ja) 2023-12-21
US20240156753A1 (en) 2024-05-16
KR20200115598A (ko) 2020-10-07
EP3746126A1 (en) 2020-12-09
AU2019214891B2 (en) 2024-08-01
MX2024001713A (es) 2024-02-20
US11911351B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
ZA201907158B (en) Methods and compositions for treating sleep apnea
IL276247A (en) Methods and materials for the treatment of sleep apnea
IL282600A (en) Composition and method for health care
IL271503A (en) Preparations and treatments for sleep disorders
PL3253443T3 (pl) Urządzenie do leczenia chrapania i bezdechu sennego
EP3092033A4 (en) Method and apparatus for treating sleep apnea
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL275626A (en) Preparations and methods for surface treatment
EP3866736A4 (en) METHODS AND DEVICES FOR THE TREATMENT OF SLEEP APNEA
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL280348A (en) Preparations and methods for surface treatment
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
LT3691649T (lt) Žaizdų gydymo kompozicijos ir būdai
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
IL260929B (en) Dental appliance system and method of forming thereof for treating sleep apnea
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
EP3658118A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY DISEASES
EP3720351A4 (en) METHODS AND SYSTEMS FOR THE TREATMENT OF SLEEP APNEA
IL307186A (en) Methods and preparations for treating sleep apnea
EP3746068A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OBSTRUCTIVE SLEEP APNEA
IL235257A (en) Snoring and sleep apnea system
GB201913589D0 (en) Systems and methods for reducing snoring and/or sleep apnea